-Ortho clinical diagnostics INTRODUCES Flagship VITROS 5600 INTEGRATED SYSTEM AND HIgh-Capacity VITROS 3600 IMMUNOdiagNOSTIC SYSTEM-
High Wycombe, United Kingdom, (15 January 2008)-Ortho Clinical Diagnostics today announced commercial availability in Europe for two new clinical laboratory systems, the flagship VITROS 5600 Integrated System and the high-capacity VITROS 3600 Immunodiagnostic System. These next generation diagnostic platforms are uniquely designed based on world-class VITROS technologies to address the needs of the modern clinical laboratory, giving patients and clinicians high-quality and reliable test results.
Workflow data and input from 60 clinical laboratories worldwide drove the innovative designs of the VITROS 5600 and 3600 Systems. Both instruments incorporate proven VITROS technologies and use the same reagents as other VITROS platforms thereby maintaining the same degree of accuracy. The compact systems do not have any water or drainage requirements, making the most of limited lab space while allowing flexibility in instrument location.
“Our mission has always been to give health professionals the highest quality tools to determine the best treatment. The introduction of the VITROS 5600 Integrated System and VITROS 3600 Immunodiagnostic System continues this mission with next generation instruments that have a broad, world class menu of assays and the capacity to support future high-impact tests,” said David Atkins, PhD, Vice President for Ortho Clinical Diagnostics, EMEA. “Ortho Clinical Diagnostics is committed to developing advanced medical tests through our investment in specific disease-state biomarkers in reproductive health, oncology, cardiology and metabolic diseases.”
About the VITROS 5600 Integrated System
The VITROS 5600 System is designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity and can perform more than 100 different chemistry, immunoassay and infectious disease assays on a single, high- quality system. In addition to its current broad menu including user-defined applications, the VITROS 5600 Integrated System will have the capability to run future tests for earlier detection of diseases.
The VITROS 5600 System incorporates a sample-centered processing approach, where individual samples are accessed independently and in parallel for chemistry and immunoassay testing. This approach can optimise turnaround time and productivity by intelligently accounting for variable sample and test mixes, eliminating the need to split the sample on the analyser or move sample trays between modules.
About the VITROS 3600 Immunodiagnostic System
The VITROS 3600 Immunodiagnostic System is designed for medium- to high-volume laboratories. The VITROS 3600 System combines three proven VITROS technologies into a single system, enabling reliable and accurate test results across a broad menu of immunoassays:
The processing speed, on-board reagent capacities and uninterrupted workflow advantages of the system allow laboratories to address peak workloads and decrease turnaround times.
About Ortho Clinical Diagnostics
Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers the high quality in-vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to ensure every patient receives blood that's safe, the right type, and the right unit. Ortho Clinical Diagnostics also brings sophisticated information management, testing technologies, automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit www.orthoclinical.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.